About Cage Pharmaceuticals
Cage Pharmaceuticals is a private company based in New York, New York. It has reported $967,490 raised in three offerings on Form D since January 2018. Its chief executive is Peter Olagunju.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 1, 2024 | May 31, 2024 | $137,490fully sold | 2 | $68,745 | EquityRule 506(b) | Form D ↗ |
| Jul 10, 2019 | Jul 12, 2019 | $480,000fully sold | 1 | $480K | EquityRule 506(b) | Form D ↗ |
| Dec 22, 2017 | Jan 5, 2018 | $350,000of $1.7M target | 1 | $350K | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $967,490 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Cage Pharmaceuticals's Form D filed May 31, 2024.
PO
Peter Olagunju
Chief Executive Officer and director
BM
Brian Malik
Director
NP
Nick Papadopoulos
Director
IR
Isaac Ro
Director
Earlier filings also listed Jason Rifkin (president and ceo, last listed Jul 2019).